Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

2,2'-{2-[(1R)-1-({[(2,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diyl}diacetic acid

EU orphan designation number: EU/3/11/899   
Active ingredient: 2,2'-{2-[(1R)-1-({[(2,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diyl}diacetic acid
Indication: Treatment of multiple myeloma
Sponsor: Takeda Development Centre Europe Ltd.
61 Aldwych, London WC2B 4AE, United Kingdom

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
29/09/2011 Centralised Orphan - Designation EMA/OD/048/11 (2011)7032 of 27/09/2011
12/11/2013 Centralised Orphan - Change of address